Current Dermatology Reports

, Volume 5, Issue 4, pp 270–277 | Cite as

Vasculitic Diseases and Prothrombotic States Contributing to Delayed Healing in Chronic Wounds

  • Victoria K. ShanmugamEmail author
Wound Care and Healing (A Friedman, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Wound Care and Healing



Autoimmune diseases are a common cause of delayed wound healing and should be considered in patients with chronic wounds who do not respond to local wound care or who fail skin grafting in the absence of infection.

Recent Findings

Epidemiologic studies have shown that, of patients with chronic wounds evaluated in specialized wound healing clinics, 20–23 % have autoimmune etiologies for their wounds including vasculitis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, pyoderma gangrenosum, and other autoimmune diseases.


In this article, autoimmune diseases known to be associated with chronic wounds and delayed wound healing are reviewed and the importance of a multidisciplinary approach for patients with chronic wounds, with involvement of rheumatology and dermatology, is highlighted. This approach allows for investigation of underlying systemic disease and improves clinical outcomes for many of these challenging patients.


Chronic wound Vasculitis Pyoderma gangrenosum Rheumatoid arthritis Lupus Leg ulcer 


Compliance with Ethical Standards

Conflict of Interest

Victoria Shanmugam reports grants from the National Institute of Nursing Research during the conduct of the study.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2009;17(6):763–71.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Escandon J, Vivas AC, Tang J, Rowland KJ, Kirsner RS. High mortality in patients with chronic wounds. Wound Repair Regen. 2011;19(4):526–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Price P, Harding K. The impact of foot complications on health-related quality of life in patients with diabetes. J Cutan Med Surg. 2000;4(1):45–50.PubMedGoogle Scholar
  4. 4.
    Körber A, Klode J, Al-Benna S, Wax C, Schadendorf D, Steinstraesser L, et al. Etiology of chronic leg ulcers in 31,619 patients in Germany analyzed by an expert survey. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2011;9(2):116–21.PubMedGoogle Scholar
  5. 5.
    Goslen JB. Autoimmune ulceration of the leg. Clin Dermatol. 1990;8(3–4):92–117.CrossRefPubMedGoogle Scholar
  6. 6.•
    Shanmugam VK, Schilling A, Germinario A, Mete M, Kim P, Steinberg J, et al. Prevalence of immune disease in patients with wounds presenting to a tertiary wound healing centre. International Wound Journal. 2011:1–9. Important article demonstrating prevalence of autoimmune disease in patients presenting to a wound clinic . Google Scholar
  7. 7.
    Li J, Chen J, Kirsner R. Pathophysiology of acute wound healing. Clin Dermatol. 2007;25(1):9–18.CrossRefPubMedGoogle Scholar
  8. 8.
    Shanmugam V, DeMaria D, Attinger C. Lower extremity ulcers in rheumatoid arthritis: features and response to immunosuppression. Clin Rheumatol. 2011;30(6):849–53.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Oien RF, Hakansson A, Hansen BU. Leg ulcers in patients with rheumatoid arthritis—a prospective study of aetiology, wound healing and pain reduction after pinch grafting. Rheumatology. 2001;40(7):816–20.CrossRefPubMedGoogle Scholar
  10. 10.•
    Jebakumar AJ, Udayakumar PD, Crowson CS, Gabriel SE, Matteson EL. Occurrence and effect of lower extremity ulcer in rheumatoid arthritis—a population-based study. J Rheumatol. 2014;41(3):437–43 .Important epidemiologic study demonstrating the prevalence and morbidity of leg ulceration in patients with rheumatoid arthritis.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Makol A, Matteson EL, Warrington KJ. Rheumatoid vasculitis: an update. Curr Opin Rheumatol. 2015;27(1):63–70.CrossRefPubMedGoogle Scholar
  12. 12.
    Assmann G, Pfreundschuh J, Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. Clin Exp Rheumatol. 2010;28(1 Suppl 57):81–3.PubMedGoogle Scholar
  13. 13.
    Sayah A, English Iii JC. Rheumatoid arthritis: a review of the cutaneous manifestations. J Am Acad Dermatol. 2005;53(2):191–209.CrossRefPubMedGoogle Scholar
  14. 14.•
    Shanmugam VK, Fernandez S, Evans KK, McNish S, Banerjee A, Couch K, et al. Postoperative wound dehiscence: predictors and associations. Wound Repair and Regeneration. 2015:n/a-n/a. Important large epidemiologic study investigating predictors of post-operative wound dehiscence.Google Scholar
  15. 15.
    Tuffaneilli DL, Dubois EL. Cutaneous manifestations of systemic lupus erythematosus. Arch Dermatol. 1964;90:377–86.CrossRefGoogle Scholar
  16. 16.
    Chia HY, Tang MB. Chronic leg ulcers in adult patients with rheumatological diseases—a 7-year retrospective review. Int Wound J. 2014;11(6):601–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Dabiri G, Falanga V. Connective tissue ulcers. Journal of Tissue Viability. 2013;22(4):92–102.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Sakakibara K, Matsumoto M, Motohashi S, Suzuki S. Recurrent refractory arterial thromboembolism in a patient with anti-phospholipid antibody syndrome. Intern Med. 2013;52(10):1145–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012;71(11):1833–8.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Shanmugam V, Price P, Attinger C, Steen V. Lower extremity ulcers in systemic sclerosis: features and response to therapy. Int J Rheumatol. 2010.Google Scholar
  21. 21.
    Hafner J, Schneider E, Burg G, Cassina PC. Management of leg ulcers in patients with rheumatoid arthritis or systemic sclerosis: the importance of concomitant arterial and venous disease. J Vasc Surg. 2001;32(2):322–9.CrossRefGoogle Scholar
  22. 22.
    Deguchi J, Shigematsu K, Ota S, Kimura H, Fukayama M, Miyata T. Surgical result of critical limb ischemia due to tibial arterial occlusion in patients with systemic scleroderma. J Vasc Surg. 2009;49(4):918–23.CrossRefPubMedGoogle Scholar
  23. 23.
    Braswell SF, Kostopoulos TC, Ortega-Loayza AG. Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol. 2015;73(4):691–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Kaur MR, Lewis HM. Severe recalcitrant pyoderma gangrenosum treated with infliximab. Br J Dermatol. 2005;153(3):689–91.CrossRefPubMedGoogle Scholar
  25. 25.
    Guenova E, Teske A, Fehrenbacher B, Hoerber S, Adamczyk A, Schaller M, et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol. 2011;147(10):1203–5.CrossRefPubMedGoogle Scholar
  26. 26.
    Perniciaro CV, Winkelmann RK, Hunder GG. Cutaneous manifestations of Takayasu’s arteritis. A clinicopathologic correlation. J Am Acad Dermatol. 1987;17(6):998–1005.CrossRefPubMedGoogle Scholar
  27. 27.
    Boudny C, Nievergelt H, Braathen LR, Simon D. Wegener’s granulomatosis presenting as pyoderma gangrenosum. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2008;6(6):477–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Carlson JA. The histological assessment of cutaneous vasculitis. Histopathology. 56(1):3–23.Google Scholar
  29. 29.
    Kawakami T, Okano T, Soma Y. Rituximab therapy for deep toe ulcer with microscopic polyangiitis refractory to corticosteroids and cyclophosphamide. J Dermatol. 2014;41(2):191–2.CrossRefPubMedGoogle Scholar
  30. 30.
    Patel FB, Couch KS, McNish S, Miller JD, Siegel R, Easley S, et al. A 66 year-old woman with hemoptysis. Arthritis Care Res (Hoboken). 2015.Google Scholar
  31. 31.
    Olin JW. Thromboangiitis obliterans (Buerger’s disease). N Engl J Med. 2000;343(12):864–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Sneller MC, Hu Z, Langford CA. A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis. Arthritis Rheum. 2012;64(3):835–42.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Dammacco F, Sansonno D. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med. 2013;369(11):1035–45.CrossRefPubMedGoogle Scholar
  34. 34.
    De Virgilio A, Greco A, Magliulo G, Gallo A, Ruoppolo G, Conte M, et al. Polyarteritis nodosa: a contemporary overview. Autoimmunity Reviews.Google Scholar
  35. 35.
    Raju RM, Raju SM, Zhao Y, Rubin EJ. Leveraging advances in tuberculosis diagnosis and treatment to address nontuberculous mycobacterial disease. Emerg Infect Dis. 2016;22(3):365–9.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Chan MP. Neutrophilic panniculitis: algorithmic approach to a heterogeneous group of disorders. Archives of Pathology & Laboratory Medicine. 2014;138(10):1337–43.CrossRefGoogle Scholar
  37. 37.
    Koshy M, Entsuah R, Koranda A, Kraus A, Johnson R, Bellvue R, et al. Leg ulcers in patients with sickle cell disease [see comments]. Blood. 1989;74(4):1403–8.PubMedGoogle Scholar
  38. 38.
    Chaine B, Neonato M, Girot R, Aractingi S. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. Arch Dermatol. 2001;137(4):467–70.PubMedGoogle Scholar
  39. 39.
    Sirieix M, Debure C, Baudot N, Dubertret L, Roux M, Morel P, et al. Leg ulcers and hydroxyurea: forty-one cases. Arch Dermatol. 1999;135(7):818–20.CrossRefPubMedGoogle Scholar
  40. 40.
    Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med. 1998;128(1):29–32.CrossRefPubMedGoogle Scholar
  41. 41.
    Shanmugam VK, McNish S, Shara N, Hubley KJ, Kallakury B, Dunning DM, et al. Chronic leg ulceration associated with polycythemia vera responding to ruxolitinib (Jakafi®). The Journal of Foot and Ankle Surgery. (0).Google Scholar
  42. 42.
    Alavi A, Hafner J, Dutz JP, Mayer D, Sibbald RG, Criado PR, et al. Atrophie Blanche: is it associated with venous disease or livedoid vasculopathy? Adv Skin Wound Care. 2014;27(11):518–24.CrossRefPubMedGoogle Scholar
  43. 43.
    Acland KM, Darvay A, Wakelin SH, Russell-Jones R. Livedoid vasculitis: a manifestation of the antiphospholipid syndrome? Br J Dermatol. 1999;140(1):131–5.CrossRefPubMedGoogle Scholar
  44. 44.
    Callen JP. Livedoid vasculopathy: what it is and how the patient should be evaluated and treated. Arch Dermatol. 2006;142(11):1481–2.CrossRefPubMedGoogle Scholar
  45. 45.
    Cardoso R, Gonçalo M, Tellechea O, Maia R, Borges C, Silva JAP, et al. Livedoid vasculopathy and hypercoagulability in a patient with primary Sjögren’s syndrome. Int J Dermatol. 2007;46(4):431–4.CrossRefPubMedGoogle Scholar
  46. 46.
    Frances C, Barete S. Difficult management of livedoid vasculopathy. Arch Dermatol. 2004;140(8):1011.CrossRefPubMedGoogle Scholar
  47. 47.
    Jorizzo JL. Livedoid vasculopathy: what is it? Arch Dermatol. 1998;134(4):491–3.CrossRefPubMedGoogle Scholar
  48. 48.
    Mimouni D, Ng PP, Rencic A, Nikolskaia OV, Bernstein BD, Nousari HC. Cutaneous polyarteritis nodosa in patients presenting with atrophie blanche. Br J Dermatol. 2003;148(4):789–94.CrossRefPubMedGoogle Scholar
  49. 49.
    Tran M, Becherel P, Cordel N, Piette JC, Frances C. “Idiopathic” livedoid vasculitis. Ann Dermatol Venerol. 2001;128:1003–7.Google Scholar
  50. 50.
    Wakelin SH, Ellis JP, Black MM. Livedoid vasculitis with anticardiolipin antibodies: improvement with danazol. Br J Dermatol. 1998;139(5):935–7.CrossRefPubMedGoogle Scholar
  51. 51.
    Winkelmann R, Schroeter A, Kierland R, Ryan T. Clinical studies of livedoid vasculitis: (segmental hyalinizing vasculitis). Mayo Clin Proc. 1974;49(10):746–50.PubMedGoogle Scholar
  52. 52.
    Hairston BR, Davis M, Pittelkow MR, Ahmed I. Livedoid vasculopathy: further evidence for procoagulant pathogenesis. Arch Dermatol. 2006;142(11):1413–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Charabaty S, Shanmugam V. A 65-year-old man with longstanding seropositive rheumatoid arthritis and lower extremity ulceration. Arthritis Care & Research. 2009;61(9):1275–80.CrossRefGoogle Scholar
  54. 54.
    Falanga V, Fine MJ, Kapoor WN. The cutaneous manifestations of cholesterol crystal embolization. Arch Dermatol. 1986;122(10):1194–8.CrossRefPubMedGoogle Scholar
  55. 55.
    Weenig RH, Sewell LD, Davis MDP, McCarthy JT, Pittelkow MR. Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol. 2007;56(4):569–79.CrossRefPubMedGoogle Scholar
  56. 56.
    Malbos S, Ureña-Torres P, Bardin T, Ea H-K. Sodium thiosulfate is effective in calcific uremic arteriolopathy complicating chronic hemodialysis. Joint Bone Spine. 2016;83(1):89–92.CrossRefPubMedGoogle Scholar
  57. 57.
    Lonowski S, Martin S, Worswick S. Widespread calciphylaxis and normal renal function: no improvement with sodium thiosulfate. Dermatology online journal. 2015;21(5).Google Scholar
  58. 58.
    Francès C, Niang S, Laffitte E. Pelletier Fl, Costedoat N, Piette JC. Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases. Arthritis & Rheumatism. 2005;52(6):1785–93.CrossRefGoogle Scholar
  59. 59.
    Wiszniewski A, Bykowska K, Bilski R, Jaśkowiak W, Proniewski J. Prevalence rate for inherited thrombophilia in patients with chronic and recurrent venous leg ulceration. Wound Repair Regen. 2011;19(5):552–8.CrossRefPubMedGoogle Scholar
  60. 60.
    Shanmugam VK, McNish S, Duncan J, Root B, Tassi E, Wellstein A, et al. Late failure of a split-thickness skin graft in the setting of homozygous factor V Leiden mutation: a case report and correlative animal model from the Wound Etiology and Healing (WE-HEAL) study. International Wound Journal. 2013:n/a-n/a.Google Scholar
  61. 61.
    Sams W. Livedo vasculitis. Therapy with pentoxifylline. Arch Dermatol. 1988;124(5):684–7.CrossRefPubMedGoogle Scholar
  62. 62.
    Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J, et al. Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial. The Lancet Haematology. 3(2):e72–e9.Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Division of Rheumatology, Department of MedicineThe George Washington University, School of Medicine and Health SciencesWashingtonUSA

Personalised recommendations